Merck & Co., Inc. (MRK)
| Market Cap | 215.32B |
| Revenue (ttm) | 64.24B |
| Net Income (ttm) | 19.03B |
| Shares Out | 2.48B |
| EPS (ttm) | 7.56 |
| PE Ratio | 11.48 |
| Forward PE | 9.89 |
| Dividend | $3.24 (3.74%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 8,319,373 |
| Open | 86.69 |
| Previous Close | 86.28 |
| Day's Range | 85.80 - 87.37 |
| 52-Week Range | 73.31 - 105.07 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 105.29 (+21.37%) |
| Earnings Date | Oct 30, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $105.29, which is an increase of 21.37% from the latest price.
News
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Merck & Co., Inc. ( MRK) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck...
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial.
Merck and Blackstone enter research agreement to develop cancer therapy for $700 million
Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 million to develop an experimental cancer therapy.
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Black...
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an ...
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
Top 10 High-Yield Dividend Stocks For November 2025
The November 2025 high-yield dividend watchlist highlights 10 stocks selected for quality, value, and attractive starting yields, aiming for a 12% CAGR. The watchlist's five-year CAGR is 14.49%, trail...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Merck & Co., Inc. ( MRK) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Carol...
My Top 10 High-Yield Picks For November 2025: One Yields 9%+
I present a diversified selection of high-yield dividend stocks with strong income and growth potential, including CVX, VZ, MO, ARCC, and others. Each company was selected for sustainable dividends, a...
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
Merck & Co., Inc. (NYSE:MRK) stock traded in a volatile session on Thursday following its third-quarter earnings report and updated fiscal 2025 outlook.
Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge
Merck published its financial results for Q3 2025 this morning. Strong demand for Winrevair from patients suffering from pulmonary arterial hypertension drove sales to $360 million in the third quarte...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Merck Profit Rises on Strong Keytruda Demand
Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise.
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower e...
Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil
Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results.
Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.
Third quarter earnings are coming. The pharmaceutical maker's stock is down 12% this year.
The setup on earnings beyond tech
The Investment Committee debate some non-mega cap names reporting in the next 24 hours.
Merck, Eisai discontinue late-stage study for liver cancer therapy
Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy to treat a type of liver cancer, after interim results showed the treatment...
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma.
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembroli...
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based ...